Crizotinib, an ATP-competitive, small molecule TKI targeting c-MET (11 nM) and ALK (24 nM), was approved by the FDA in 2011 to treat Anaplastic Lymphoma Kinase-rearranged (ALK + ) non-small cell lung cancer (NSCLC). This evidence concerns the gene ALK and non-small cell lung carcinoma.